Thanks Daniel. Under the Melanoma 'family' patents, it says the provisional patents cover "multiple uses of bisantrene in combination with other drugs". Yesterday's news foreshadowed that Zantrene may provide an effective single agent treatment for some Melanomas - would this use case be covered under any of our patents?
General Comments / Chat, page-4137
-
- There are more pages in this discussion • 6,887 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.83 |
Change
0.020(1.11%) |
Mkt cap ! $310.7M |
Open | High | Low | Value | Volume |
$1.81 | $1.83 | $1.79 | $142.0K | 78.77K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 500 | $1.81 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.83 | 641 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 500 | 1.810 |
3 | 7009 | 1.790 |
1 | 450 | 1.780 |
1 | 651 | 1.775 |
3 | 17043 | 1.770 |
Price($) | Vol. | No. |
---|---|---|
1.825 | 641 | 1 |
1.830 | 1209 | 2 |
1.835 | 651 | 1 |
1.840 | 4651 | 3 |
1.845 | 2746 | 1 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online